Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIC: Nelonemdaz in Acute Ischemic Stroke
NCT02831088Phase 2Unknown
- Sponsor
- GNT Pharma
- Start
- Jul 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of salfaprodil in ischemic stroke (3 arms), sponsored by GNT Pharma. Primary endpoints: Proportion of subjects with modified Rankin Scale (mRS) 0-2 at 12 weeks and Occurrence rate of cerebral hemorrhagic transformation at 12 weeks. Status: unknown.
02
Drugs
salfaprodil
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02831088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831088.